NTES-S
09999
JD HEALTH
06618
BABA-W
09988
4
BOSS ZHIPIN-W
02076
5
ALI HEALTH
00241
(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (Q6)Jun 30, 2020 | (FY)Dec 31, 2019 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | 27.25%15.65B | -27.01%22.9B | -27.21%12.3B | -21.36%31.38B | -18.49%16.9B | 12.42%39.9B | 20.73%20.73B | 36.30%35.5B | 40.15%17.17B | 32.91%26.04B |
Operating income | 27.25%15.65B | -27.01%22.9B | -27.21%12.3B | -21.36%31.38B | -18.49%16.9B | 12.42%39.9B | 20.73%20.73B | 36.30%35.5B | 40.15%17.17B | 32.91%26.04B |
Cost of sales | -55.79%-13.63B | 4.88%-20.45B | 24.97%-8.75B | 21.48%-21.5B | 13.20%-11.66B | -20.74%-27.38B | -24.34%-13.44B | -36.97%-22.68B | -44.11%-10.81B | -37.52%-16.56B |
Operating expenses | -55.79%-13.63B | 4.88%-20.45B | 24.97%-8.75B | 21.48%-21.5B | 13.20%-11.66B | -20.74%-27.38B | -24.34%-13.44B | -36.97%-22.68B | -44.11%-10.81B | -37.52%-16.56B |
Gross profit | -43.14%2.02B | -75.16%2.45B | -32.20%3.55B | -21.10%9.88B | -28.24%5.23B | -2.32%12.52B | 14.61%7.29B | 35.14%12.82B | 33.88%6.36B | 25.56%9.48B |
Selling expenses | 19.58%-316.38M | 36.03%-712.37M | 27.62%-393.42M | 20.03%-1.11B | 7.50%-543.55M | -27.02%-1.39B | -31.88%-587.59M | -11.35%-1.1B | -4.29%-445.56M | -25.26%-984.47M |
Administrative expenses | 11.75%-584.47M | 10.81%-1.4B | 15.56%-662.3M | 17.88%-1.57B | 22.65%-784.35M | -23.70%-1.91B | -55.81%-1.01B | -9.53%-1.55B | -3.01%-650.82M | 4.70%-1.41B |
Revaluation surplus | -56.83%-728.53M | -1,847.84%-1.71B | -941.09%-464.54M | -105.13%-87.76M | -103.79%-44.62M | -18.36%1.71B | -2.30%1.18B | -12.47%2.1B | 48.23%1.21B | -4.24%2.39B |
-Changes in the fair value of investment property | -56.83%-728.53M | -1,847.84%-1.71B | -941.09%-464.54M | -105.13%-87.76M | -103.79%-44.62M | -18.36%1.71B | -2.30%1.18B | -12.47%2.1B | 48.23%1.21B | -4.24%2.39B |
Impairment and provision | 51.49%-61.52M | -0.76%-183.62M | -274.73%-126.82M | 24.52%-182.23M | 175.71%72.58M | -60.94%-241.42M | -83.40%-95.86M | -425.33%-150M | ---52.27M | ---28.55M |
-Other impairment is provision | 51.49%-61.52M | -0.76%-183.62M | -274.73%-126.82M | 24.52%-182.23M | 175.71%72.58M | -60.94%-241.42M | -83.40%-95.86M | -425.33%-150M | ---52.27M | ---28.55M |
Special items of operating profit | -3,069.05%-161.43M | 69.44%-293.5M | 100.88%5.44M | -169.09%-960.54M | -184.94%-619.71M | 654.69%1.39B | 237.81%729.56M | -80.13%184.23M | 30.74%215.97M | 328.48%927.11M |
Operating profit | -91.35%164.81M | -130.95%-1.85B | -42.47%1.91B | -50.61%5.96B | -55.84%3.31B | -1.86%12.07B | 13.06%7.5B | 18.53%12.3B | 42.03%6.64B | 29.71%10.38B |
Financing income | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---899.78M |
Financing cost | 63.44%-570.94M | 43.91%-1.35B | -19.12%-1.56B | -454.06%-2.41B | -267.80%-1.31B | -239.14%-434.72M | 64.08%-356.38M | --312.43M | -58.19%-992.16M | ---- |
Special items of earning before tax | -174.87%-552.97M | 100.71%1.24B | 34.57%738.58M | 21.30%616.09M | -8.29%548.83M | -23.85%507.9M | 61.00%598.42M | 77.51%666.99M | 45.05%371.68M | 100.69%375.76M |
Earning before tax | -188.55%-959.11M | -147.00%-1.96B | -57.54%1.08B | -65.66%4.17B | -67.06%2.55B | -8.55%12.15B | 28.74%7.74B | 34.77%13.28B | 39.86%6.01B | 44.66%9.86B |
Tax | -37.46%-1.09B | 75.88%-616.92M | 40.86%-791.19M | 46.85%-2.56B | 49.83%-1.34B | -7.69%-4.81B | -5.82%-2.67B | -16.40%-4.47B | -36.03%-2.52B | -21.25%-3.84B |
After-tax profit from continuing operations | -801.12%-2.05B | -259.73%-2.58B | -75.94%291.92M | -78.01%1.61B | -76.10%1.21B | -16.78%7.34B | 45.28%5.08B | 46.49%8.82B | 42.75%3.49B | 64.98%6.02B |
Earning after tax | -801.12%-2.05B | -259.73%-2.58B | -75.94%291.92M | -78.01%1.61B | -76.10%1.21B | -16.78%7.34B | 45.28%5.08B | 46.49%8.82B | 42.75%3.49B | 64.98%6.02B |
Minority profit | 246.23%576.16M | -98.57%16.65M | -66.47%166.41M | -10.58%1.17B | -56.85%496.37M | -51.11%1.31B | -7.59%1.15B | 40.05%2.67B | 100.97%1.24B | 177.38%1.91B |
Profit attributable to shareholders | -2,189.77%-2.62B | -681.93%-2.59B | -82.49%125.51M | -92.61%445.75M | -81.74%716.91M | -1.86%6.03B | 74.53%3.93B | 49.47%6.14B | 23.03%2.25B | 38.87%4.11B |
Basic earnings per share | -2,852.17%-0.633 | -747.47%-0.641 | -86.39%0.023 | -93.16%0.099 | -82.08%0.169 | -1.63%1.447 | 75.93%0.943 | 46.51%1.471 | 18.82%0.536 | 41.41%1.004 |
Diluted earnings per share | -2,852.17%-0.633 | -747.47%-0.641 | -86.39%0.023 | -93.16%0.099 | -82.08%0.169 | -1.63%1.447 | 75.93%0.943 | 46.51%1.471 | 19.38%0.536 | 51.20%1.004 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
Auditor | -- | Kaiyuan Shun Tak Certified Public Accountants Limited | -- | Kaiyuan Shun Tak Certified Public Accountants Limited | -- | Kaiyuan Shun Tak Certified Public Accountants Limited | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.